Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLOG vs mFOLFIRINOX in First-line Locally Advanced or Metastatic Pancreatic Cancer
NCT03443492Phase 2Completed
- Sponsor
- National Health Research Institutes
- Start
- Mar 2018
- Primary completion
- Nov 2019
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur, gemcitabine, oxaliplatin and folinic acid in pancreatic cancer (PC) (2 arms), sponsored by National Health Research Institutes. Primary endpoint: Progression-Free Survival at 1 year. Started Mar 2018; status: completed.
02
Drugs
tegafurgemcitabineoxaliplatinfolinic acid
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03443492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443492.